OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Clinical Immunology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Immune-epidemiological parameters of the novel coronavirus – a perspective	146
Natural history of COVID-19 and therapeutic options	94
Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients	85
Global systematic review of primary immunodeficiency registries	74
Circulating Calprotectin as a Biomarker of COVID-19 Severity	70
A comparative review of immunoassays for COVID-19 detection	70
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis	62
The role of IL-6 and IL-6 blockade in COVID-19	60
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19	54
SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives	52
Update on pollen-food allergy syndrome	47
Breast implant illness: scientific evidence of its existence	46
Systemic lupus erythematosus and risk of infection	45
Early-life exposure to air pollution and childhood allergic diseases: an update on the link and its implications	40
Atopic phenotypes and their implication in the atopic march	34
Ataxia-telangiectasia: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management	27
The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review	27
The emerging role of type 2 inflammation in asthma	26
Epidemiology of rheumatoid arthritis: genetic and environmental influences	25
Cancer risk in patients with psoriasis: should we be paying more attention?	25
Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis	25
Revisiting the complement system in systemic lupus erythematosus	25
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults	24
Generalized pustular psoriasis: current management status and unmet medical needs in Japan	24
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection	24

Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation	23
New insights into the progression from cutaneous lupus to systemic lupus erythematosus	22
The infection risks of JAK inhibition	21
Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus	21
Abrocitinib for the treatment of atopic dermatitis	21
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives	21
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials	21
Gut microbiota in Celiac Disease: microbes, metabolites, pathways and therapeutics	21
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis	20
Emerging therapy options for IgG4-related disease	20
Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion	20
Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis	20
Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies	19
Mechanical ventilation in Guillain–Barré syndrome	19
Metabolic Syndrome and psoriatic arthritis: considerations for the clinician	19
The pathogenic oral–gut–liver axis: new understandings and clinical implications	18
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis	18
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events	18
An update on VEXAS syndrome	18
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data	18
Is post-COVID syndrome an autoimmune disease?	17
The role of PCSK9 in inflammation, immunity, and autoimmune diseases	17
Rheumatoid arthritis related interstitial lung disease	17
Multimorbidity and comorbidity in psoriatic arthritis – a perspective	17
Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits	17
Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review	16
Therapeutic targeting of the IL-13 pathway in skin inflammation	16
Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology	16
A 2020 update on the use of genetic testing for patients with primary immunodeficiency	16
Elimination diets for eosinophilic esophagitis: making the best choice	16
An immunologist’s guide to immunosenescence and its treatment	16
The current status of biological treatment for uveitis	15
A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progressi	15
Gut inflammation in CVID: causes and consequences	15
Impact of resolvin mediators in the immunopathology of diabetes and wound healing	15
Ruxolitinib for the treatment of graft-versus-host disease	15
HMGB1 in nasal inflammatory diseases: a reappraisal 30 years after its discovery	14
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis	14
Emerging therapies for ulcerative colitis	14
Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic	14
Autoimmune hemolytic anemia: causes and consequences	14
Biomarkers of chronic spontaneous urticaria and their clinical implications	13
Glucocorticoids in rheumatoid arthritis still on first line: the reasons	13
Tofacitinib for the treatment of active ankylosing spondylitis in adults	13
Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions	13
Comorbid allergic rhinitis and asthma: important clinical considerations	12
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives	12
The clinical implications of the microbiome in the development of allergy diseases	12
Gut immune homeostasis: the immunomodulatory role of Bacillus clausii, from basic to clinical evidence	12
Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis	12

Chimeric antigen receptor T-cell therapy for melanoma	12
Nanoparticle-based immunotherapy: state of the art and future perspectives	11
Recent issues in JAK inhibitor safety: perspective for the clinician	11
The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection	11
Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS)	11
A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transp	11
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment	11
Convalescent plasma and hyperimmune globulin therapy in COVID-19	11
Heterogeneity in myasthenia gravis: considerations for disease management	11
Myosin light chain kinase regulates intestinal permeability of mucosal homeostasis in Crohn’s disease	11
Allergic contact dermatitis in children	11
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis	11
Dupilumab for the treatment of adolescents with atopic dermatitis	11
Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management	10
Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2	10
Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights	10
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection	10
New frontiers in precision medicine for Sjogren’s syndrome	10
Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis	10
Avacopan for the treatment of ANCA-associated vasculitis	10
Current concepts underlying the pathophysiology of acute Charcot neuroarthropathy in the diabetic foot and ankle	10
Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia	10
Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis	10
Diagnosis and management of hypersensitivity reactions to vaccines	10
Autism spectrum disorders and natural killer cells: a review on pathogenesis and treatment	10
Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives	10
In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis	9
Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis	9
Diagnosis and treatment of non-allergic rhinitis: focus on immunologic mechanisms	9
Ixekizumab for the treatment of ankylosing spondylitis	9
Clinical relevance of T follicular helper cells in systemic lupus erythematosus	9
Challenges in uncontrolled asthma in pediatrics: important considerations for the clinician	9
BRAF inhibitors and their immunological effects in malignant melanoma	9
Comparing available JAK inhibitors for treating patients with psoriasis	9
A new case of congenital ficolin-3 deficiency with primary immunodeficiency	9
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic	9
An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications	9
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab	8
Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus	8
Hematopoietic stem cell transplantation in systemic autoinflammatory diseases - the first one hundred transplanted patients	8
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients	8
Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis	8
Predicting lupus flares: epidemiological and disease related risk factors	8
Food allergy severity prediction: quite a way to go yet?	8
Regulation of crystal induced inflammation: current understandings and clinical implications	8
Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review	8
Mast cell activation: beyond histamine and tryptase	8
Model-based computational precision medicine to develop combination therapies for autoimmune diseases	8
Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency	8
Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia	8
Oral immunotherapy for food allergy in children: is it worth it?	8
Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics	7
TL1A as a therapeutic target in inflammatory bowel disease	7
Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances	7
Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives	7
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives	7
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice	7
IgG4-related disease: advances in pathophysiology and treatment	7
Comparing treatment options for large vessel vasculitis	7
Diagnosis and clinical management of Wiskott–Aldrich syndrome: current and emerging techniques	7
Current treatment options and long-term outcomes in patients with eosinophilic esophagitis	7
Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy	7
An updated review on Mendelian susceptibility to mycobacterial diseases– a silver jubilee celebration of its first genetic diagnosis	7
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making	7
DEL-1: a potential therapeutic target in inflammatory and autoimmune disease?	7
Recent insights into the pathogenesis of autoimmune hypophysitis	7
Serum exosomal long noncoding RNA nuclear-enriched abundant transcript 1 predicts 90-day mortality in acute-on-chronic hepatitis B liver failure	7
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial	7